Skip to main content

Design of 2 phase 3, double-blind, placebo-controlled, global trials of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with active systemic lupus erythematosus

  • Sponsored by Bristol Myers Squibb
Aug 21, 2023 5:05 am